You are here:

NICE
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers

Rituximab for the first-line treatment of chronic lymphocytic leukaemia

Technology appraisal guidance
Reference number: TA174
Published: 22 July 2009

Guidance
Tools and resources
Information for the public
History

Appendix B: GE decision paper - March 2014

Appendix B: GE decision paper - March 2014

Appendix B: GE decision paper - March 2014
08 April 2014
(110.09 Kb 32 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 08 April 2014